Iron-chelating therapy for iron overload disorders
The 16th International Symposium on Applied Bioinorganic Chemistry (ISABC 2023) was held in Ioannina, Greece, in June 2023, organised by the University of Ioannina. It linked molecular design with advances in the diagnosis, treatment and monitoring of metal-related disorders.
Iron-chelating therapy uses agents to bind excess iron and support its removal from the body. It is relevant to hereditary haemochromatosis, thalassaemia, myelodysplastic syndromes and transfusion-dependent anaemia, where accumulated metal can affect the liver, heart, pancreas and joints. Treatment must be matched to the cause and severity of overload.
For Australian readers, this science meets a mixed public and private health system, specialist referral pathways, community pharmacies and remote care. Major treatment centres in Melbourne, Sydney, Brisbane, Perth and Adelaide provide concentrated expertise, while people outside metropolitan areas often travel further for infusions, blood tests and multidisciplinary review.
The symposium also strengthened links among emerging researchers, clinicians and industry. Young scientist travel awards, poster prizes, scholarships and clear application requirements supported participation, while Zita Congress & Event Management served as the official secretariat for registration, accommodation and abstract-related inquiries.
The clinical burden of excess iron
Iron supports oxygen transport, but excess labile iron can generate reactive oxygen species and damage tissues. In hereditary haemochromatosis, transfusional iron overload and related disorders, the resulting risks may include liver disease, cardiomyopathy, diabetes and joint problems. Symptoms can be nonspecific, so ferritin and transferrin saturation are interpreted alongside blood tests, medical history and genetic findings.
Chelation reduces the iron burden rather than curing the underlying genetic or blood-production disorder. Its goals, frequency and duration depend on iron measurements, organ function, blood loss and transfusion history; excessive treatment can cause iron deficiency. For hereditary haemochromatosis, therapeutic phlebotomy remains a common standard, while chelation is used in selected circumstances.
Chelators and clinical roles
Deferoxamine is a parenteral chelator delivered by infusion or subcutaneous administration. Deferasirox is available in oral formulations, while deferiprone provides another oral option. Approved indications, available presentations and subsidy status differ, so a medicine suitable in one setting may not be available or reimbursed identically elsewhere.
Agent selection depends on the source of overload, liver and kidney function, blood counts, joint tolerance and adherence. Paediatric and transfusion-dependent patients require particularly careful dosing and monitoring of growth, development and organ function.
Researchers tracing earlier scientific discussions can consult the historical conference resource for background on evolving questions in iron chelation. Current clinical guidance should remain the basis for treatment decisions.
Navigating Australian care pathways
Australian care often begins with a general practitioner and referral to haematology, hepatology or genetics services. People with transfusion-dependent anaemia may already have a specialist team, while people with haemochromatosis can enter care through family screening. Public hospital treatment is generally coordinated through Medicare, and private specialist care can provide another route.
The Therapeutic Goods Administration regulates therapeutic goods under the Therapeutic Goods Act 1988, with approved products included in the Australian Register of Therapeutic Goods. PBS listing and current clinical guidelines determine subsidised access for some medicines, but eligibility can depend on the formulation, indication and treatment setting. Prescribers therefore need to check requirements rather than assume hospital or community availability.
Monitoring combines ferritin and transferrin saturation with kidney and liver function tests, blood counts and agent-specific safety checks. Deferiprone requires particular attention to neutropenia, deferasirox to renal and hepatic effects, and both deferasirox and deferoxamine to hearing and vision assessment.
Geography, routines and treatment access
Living outside a capital city can add travel, accommodation and missed-work costs to treatment. Some patients use local pathology services for blood tests while attending a tertiary centre for specialist review, with telehealth used where appropriate and available. Community pharmacies may also supply oral medicines, although temperature-controlled storage requirements can complicate collection for some formulations.
Treatment schedules must fit ordinary Australian routines involving work, school, commuting and family care. Long infusions may require planning around leave, childcare and transport, while hot weather can make repeated travel uncomfortable. A workable plan combines clinical appointments with local collection, pharmacy access and clear responsibilities for patients, carers and clinicians.
Research networks and symposium exchange
Australian researchers can connect university laboratories, metropolitan hospitals, regional services and patient organisations through multicentre studies, disease registries and biobanks. International meetings help teams compare dosing experience, identify research gaps and develop common outcome measures. Ethical review, informed consent and appropriate governance of sensitive health data remain central to translating laboratory findings into clinical studies.
Travel support was part of the meeting’s participation model, and the scholarship deadline updates provided deadline changes and application information. Poster prizes and young scientist awards also encouraged early-career researchers to present findings and receive feedback from specialists in applied bioinorganic chemistry.
Future collaboration can focus on better iron biomarkers, safer drug delivery, adherence support and equitable access. Such work benefits from involving clinicians, pharmacists, nurses, genetic counsellors and people with lived experience from the outset rather than after a treatment protocol has been developed.
Comparing the main chelation options
The main agents differ in route, monitoring requirements and practical use. Availability in Australia and PBS support should be checked for the specific medicine, formulation and indication, while the following comparison is educational rather than a prescribing guide.
| Agent | Administration | Clinical emphasis | Key monitoring and practical issues |
|---|---|---|---|
| Deferoxamine | Infusion or subcutaneous injection | Parenteral iron removal, including transfusion-related overload | Ferritin, transferrin saturation, kidney function, hearing and vision; infusion time and site care |
| Deferasirox | Oral tablet or dispersible granules | Oral chelation for selected iron-overload settings | Kidney and liver function, gastrointestinal effects, hearing and vision; adherence and pharmacy supply |
| Deferiprone | Oral medicine | Oral treatment for certain iron-overload indications | Neutrophils because of agranulocytosis risk, liver function, joint and gastrointestinal effects; suitability and subsidy vary |
Treatment choice remains individual. Clinicians must assess the cause of overload, existing complications, contraindications, patient preferences and the practical demands of each regimen.
Building a coordinated response
Clinicians and researchers can act by auditing referral, prescribing and monitoring pathways for people with iron overload. Early-career teams can build collaborations around Australian cohorts, trial readiness and shared outcome measures, while professional networks can help ensure that molecular advances reach patients outside major centres.
Engage with the ISABC scientific community through the official symposium site and contact Zita Congress & Event Management, the designated secretariat, for registration, accommodation and abstract-related support. The goal is coordinated care that keeps effective iron removal available, safe and connected to each patient’s daily life.